Results 211 to 220 of about 638,404 (291)

Phase Separation of TRIM21 Modulates PTPN14 Stability to Drive Flow‐Dependent Endothelial Activation and Atherogenesis

open access: yesAdvanced Science, EarlyView.
Disturbed flow promotes the formation of TRIM21‐rich biomolecular droplets, which concentrate TRIM21 and PTPN14 and facilitate their SPRY‐FERM interaction (illustrated by the TRIM21 D355‐PTPN14 R132 salt bridge). This condensate‐driven proximity enables TRIM21 to catalyze K48‐linked polyubiquitination of PTPN14 at lysine 956, leading to proteasome ...
Xue He   +10 more
wiley   +1 more source

Natural‐Inspired Engineered Microalgae With Selenium Enrichment Enabled Potent Anti‐Tumor Immunity

open access: yesAdvanced Science, EarlyView.
Se‐Ssp was engineered as a potent immunomodulator for activating innate immunity via the TLR and cGAS‐STING pathways, therefore converting “cold” tumors into “hot” tumors to achieve high efficacy and long‐term therapeutic outcomes. ABSTRACT Immunotherapy has shed light on clinical oncology for several decades.
Yuqi Yang   +11 more
wiley   +1 more source

Different risk factors for advanced colorectal neoplasm in young adults. [PDF]

open access: yesWorld J Gastroenterol, 2016
Kim JY   +9 more
europepmc   +1 more source

Low SLC8A1 in Colorectal Cancer Dictates Radiotherapy Resistance Through Calcium‐Dependent ANXA2+sEVs Driving M2 Polarization of TAMs

open access: yesAdvanced Science, EarlyView.
SLC8A1 deficiency in colorectal cancer cells increases intracellular calcium signaling, promoting the secretion of ANXA2‐enriched small extracellular vesicles. These vesicles reprogram tumor‐associated macrophages towards an M2 phenotype, which in turn fosters a tumor microenvironment conducive to radioresistance and is associated with poor patient ...
Yimin Fang   +18 more
wiley   +1 more source

Autophagy Orchestrates Anti‐Tumor Immunity to Enhance Chemosensitivity via the FBXW2/C/EBPβ/TIMP‐2 Axis in Colorectal Cancer

open access: yesAdvanced Science, EarlyView.
Chemotherapy leverages tumor‐cell autophagy to reshape the colorectal cancer immune microenvironment. Autophagy degrades FBXW2 to promote C/EBPβ‐mediated TIMP‐2 transcription and MMP‐9 suppression, driving intra‐tumoral CD8+ T‐cell infiltration. Targeting MMP‐2/9 or restoring TIMP‐2 overcomes chemo‐resistance in autophagy‐deficient tumors. ABSTRACT The
Bing Cheng   +12 more
wiley   +1 more source

Tissue‐Agnostic Cellular Morphometric Biomarkers for Risk‐Adapted Management Across Gastrointestinal Precancerous Lesions and Cancers

open access: yesAdvanced Science, EarlyView.
An interpretable, unsupervised artificial intelligence framework identifies a 13‐cellular morphometric biomarker (CMB) signature from routine H&E whole‐slide images. Validated across 2,602 patients, the fixed signature generalizes across colorectal, gastric, and esophageal tissues without retraining, stratifies prognosis and precancerous lesion risk ...
Pin Wang   +14 more
wiley   +1 more source

Macrophage PABPC4‐SPP1 Axis Orchestrates Immunosuppression in Colorectal Cancer

open access: yesAdvanced Science, EarlyView.
In the CRC microenvironment, macrophage PABPC4 binds to the 3′UTR of SPP1 mRNA to stabilize its expression, thereby sustaining M2‐like immunosuppressive macrophage polarization. Concurrently, this axis suppresses CD8+ T cell effector functions via CD44 signaling, collectively fostering an immunosuppressive niche that drives tumor progression.
Meng Wang   +14 more
wiley   +1 more source

Corynoxine Inhibits Tumor Growth via Targeting NQO1 and Modulating the PTPA–NQO1/PP2A Switch to Activate PP2A

open access: yesAdvanced Science, EarlyView.
Corynoxine exerts potent broad‐spectrum anticancer activity by directly targeting NQO1. This interaction dissociates the oncogenic NQO1‐PTPA complex, releasing PTPA to robustly activate the tumor suppressor PP2A. Consequently, downstream Raf/MEK/ERK and PI3K/AKT signaling pathways are suppressed, downregulating c‐Myc and driving tumor regression ...
Guoqing Hou   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy